Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914)

Renal

- Localized
  - T1b or greater (has not spread beyond the kidney)
    - No Prior Systemic Therapy
      - IRB# 20148: X184-313: Phase 3 Randomized Study of Cabozantinib with Nivolumab and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
      - IRB# 19991: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
    - Nephrectomy Candidate
      - IRB# 19661: EA8143: Phase 3 Randomized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)
    - Prior Systemic Therapy
      - No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor
        - IRB# 19283: Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC
        - IRB# 17027: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology
        - IRB# 19946: Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914)
  - Metastatic/locally advanced
    - Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4
      - Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies
- Non-Clear Cell
  - Papillary Renal Carcinoma
    - IRB# 20977: Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior Therapy

CROSS-DISEASE TRIALS

- IRB# 19992: EAY 131 (MATCH)
- IRB# 18084: S1609 (DART)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

02 July 2020